Every year, approximately 178 million people worldwide sustain a bone fracture — from simple stress fractures in runners to complex comminuted fractures from road traffic accidents. While the skeleton has a remarkable innate capacity for self-repair, roughly 5–10% of fractures fail to heal within the expected timeframe, progressing to delayed union or non-union — a painful, disabling condition where the bone ends refuse to bridge despite months of immobilization [1]. Current treatment for non-union typically requires revision surgery with autologous bone grafting — harvesting bone from the patient's iliac crest — which carries donor-site morbidity in up to 30% of cases and still fails in approximately 10–20% of revisions. Mesenchymal stem cell (MSC) therapy is being investigated as a biological alternative that delivers the cellular machinery of bone formation — osteoprogenitor cells, angiogenic factors, and immunomodulatory signals — directly to the fracture gap [2].

The Biology of Bone Healing — and Why It Sometimes Fails

Bone heals through a precisely orchestrated sequence of events that recapitulates embryonic skeletal development. The process unfolds in four overlapping phases: hematoma formation and inflammation, soft callus formation (cartilaginous), hard callus formation (bony), and remodeling [3].

The inflammatory phase sets the stage. Immediately after fracture, ruptured blood vessels create a hematoma rich in platelets, macrophages, and mesenchymal progenitor cells. Pro-inflammatory cytokines — TNF-α, IL-1β, and IL-6 — peak within 24 hours, recruiting additional immune cells and MSCs from the periosteum, endosteum, and bone marrow. This acute inflammation is not pathological; it is the essential trigger for the entire healing cascade. Patients on chronic NSAIDs or corticosteroids during this window show measurably delayed union, underscoring inflammation's necessary role [4].

Soft callus: the cartilaginous template. By days 5–10, MSCs recruited to the fracture site differentiate into chondrocytes under the influence of TGF-β and BMP-2, forming a fibrocartilaginous soft callus that stabilizes the fracture ends. This is endochondral ossification — the same process by which long bones form during fetal development. The soft callus progressively mineralizes as chondrocytes undergo hypertrophy and apoptosis, releasing matrix vesicles rich in calcium and phosphate that seed hydroxyapatite crystal formation [5].

Hard callus and remodeling. By weeks 3–6, woven bone replaces the mineralized cartilage through osteoblast activity driven by Wnt/β-catenin signaling and Runx2 — the master transcription factor for osteoblastogenesis. The resulting hard callus is biomechanically competent but structurally disorganized. Over the subsequent months to years, osteoclasts resorb excess bone and osteoblasts deposit organized lamellar bone along lines of mechanical stress (Wolff's law), restoring the original bone architecture [6].

Why non-union occurs. Healing fails when any of these phases is disrupted. The most common causes include: insufficient vascular supply (smokers, diabetics, elderly patients), mechanical instability (inadequate fixation), infection (especially in open fractures), and biological deficiency — a depleted or dysfunctional local MSC pool. Atrophic non-unions, in particular, show histologically acellular fibrous tissue at the fracture gap with negligible osteogenic activity — the biological machinery of bone formation is simply absent [7]. This is precisely the deficit that MSC therapy aims to correct.

MSC-mediated bone callus formation — osteoblasts and chondrocytes differentiating within a fracture gap
The four-stage process of MSC-mediated fracture healing: from hematoma and inflammation through soft and hard callus formation to final remodeling.

How MSCs Promote Bone Regeneration — The Dual Mechanism

MSCs promote bone healing through two complementary mechanisms: direct differentiation into bone-forming cells and indirect paracrine orchestration of the local repair environment [8].

Direct osteogenic differentiation. When delivered to a fracture site, a subpopulation of MSCs integrates into the callus and differentiates along the osteoblastic lineage under the influence of local BMPs and mechanical signals. These cells express alkaline phosphatase, deposit osteoid (unmineralized bone matrix), and ultimately become osteocytes embedded within mineralized bone. Labeling studies in animal models confirm that transplanted MSCs contribute directly to new bone formation, accounting for approximately 15–30% of callus osteoblasts [9].

The paracrine secretome — the primary mechanism. The majority of the therapeutic benefit, however, comes from the MSC secretome — the cocktail of growth factors, cytokines, extracellular vesicles, and microRNAs that MSCs release into their environment. Key constituents include: VEGF and FGF-2 (angiogenesis), BMP-2 and BMP-7 (osteogenic differentiation of host progenitor cells), TGF-β1 (chondrogenesis and matrix production), PDGF (recruitment of additional MSCs and pericytes), and IGF-1 (osteoblast proliferation). MSCs also release exosomes containing microRNAs — particularly miR-21, miR-199a, and miR-218 — that enhance osteogenic gene expression in recipient cells [10].

Immunomodulation at the fracture site. Chronic low-grade inflammation at a non-union site — driven by persistently elevated TNF-α and IL-1β — inhibits osteoblast differentiation and promotes fibrosis instead of bone formation. MSCs shift the local immune milieu from a pro-inflammatory M1 macrophage phenotype to a pro-regenerative M2 phenotype, secreting IL-10, TGF-β, and PGE2. This resolves the chronic inflammatory blockade and restores conditions permissive for osteogenesis [11].

Preclinical Evidence — What Animal Models Tell Us

The preclinical literature on MSC-mediated bone repair is extensive and consistently positive across multiple species and fracture models.

Rodent critical-size defect models. In rat and mouse femoral and calvarial critical-size defects — gaps too large to heal spontaneously — MSC-seeded scaffolds consistently achieve bridging rates of 70–95% compared to 0–20% with scaffold alone. A 2020 systematic review of 47 rodent studies found that MSC treatment increased bone volume fraction at the defect site by a weighted mean of 2.4-fold relative to controls, with bone marrow-derived MSCs and adipose-derived MSCs showing comparable efficacy [12].

Large-animal models. Ovine (sheep) and caprine (goat) tibial osteotomy models more closely approximate human fracture biomechanics and scale. In a 2019 study, ovine tibial defects treated with autologous bone marrow MSCs on a β-TCP carrier achieved radiographic union in 85% of cases at 12 weeks, compared to 40% with carrier alone. Histomorphometry confirmed significantly higher bone volume, trabecular thickness, and biomechanical strength in the MSC group — approaching that of intact bone [13].

Atrophic non-union models. Particularly compelling are studies in established non-union models, where a fracture is allowed to progress to atrophic non-union before treatment. In a rabbit radius non-union model, percutaneous injection of bone marrow MSCs at 8 weeks post-fracture — after non-union was radiographically confirmed — achieved bony bridging in 78% of animals by 16 weeks, compared to 11% with saline injection. This is the scenario most clinically relevant: treating an existing non-union, not merely augmenting primary fracture healing [14].

Clinical Evidence — From Case Series to Randomized Trials

Human data on MSC therapy for bone healing is growing steadily, though it remains predominantly at the case-series and small-RCT level rather than large multicenter phase III trials.

Long bone non-union. The largest published series to date includes 132 patients with established non-union of the tibia, femur, or humerus treated with percutaneous injection of autologous bone marrow concentrate (containing MSCs) combined with a demineralized bone matrix carrier. At a minimum 2-year follow-up, 78% achieved clinical and radiographic union without additional surgery, with a median time to union of 14 weeks. Subgroup analysis identified smoking and infection as the strongest negative predictors of success [15].

Randomized controlled data. A 2021 multicenter RCT randomized 60 patients with tibial non-union to either standard iliac crest bone grafting (ICBG) or bone marrow-derived MSCs expanded ex-vivo and seeded onto a β-TCP scaffold. At 12 months, the MSC group achieved union in 83% versus 77% for ICBG — statistically non-inferior — but with zero cases of donor-site morbidity in the MSC arm versus 33% chronic harvest-site pain in the ICBG arm. The MSC group also had significantly shorter operative time and hospital stay [16].

Femoral head osteonecrosis. In early-stage osteonecrosis of the femoral head — a condition where compromised blood supply leads to bone death and eventual collapse — core decompression augmented with bone marrow MSC injection has shown promise. A meta-analysis of 10 studies including 528 hips found that MSC-augmented core decompression reduced the rate of radiographic progression and conversion to total hip arthroplasty by approximately 25 percentage points at 3–5 year follow-up compared to core decompression alone [17].

The VELAR Approach to MSC-Mediated Bone Repair

At VELAR Center, MSC therapy for bone healing is delivered as part of a coordinated orthopedic protocol, not an isolated injection. The goal is to optimize the biological environment so the transplanted cells have the best possible conditions to function.

Step 1 Comprehensive assessment — weight-bearing X-rays, CT if indicated, review of surgical fixation stability, and screening for metabolic contributors (Vitamin D, calcium, thyroid function)
Step 2 Source selection — Wharton's jelly-derived MSCs are selected for their high proliferative capacity and consistent quality; they express CD73, CD90, and CD105 per ISCT criteria with ≥95% purity
Step 3 Image-guided delivery — MSCs are delivered to the fracture gap under fluoroscopic or ultrasound guidance to ensure precise placement at the non-union site
Step 4 Follow-up Radiographic monitoring at 6, 12, and 24 weeks with functional outcome scoring; adjunctive physical therapy and nutritional optimization throughout

Realistic Expectations — What MSC Therapy Can and Cannot Do

An honest assessment. MSC therapy for bone healing is a promising biological adjunct, not a magic solution. It cannot compensate for unstable fixation, uncontrolled infection, or severe systemic disease. The evidence supports its use as a graft alternative or augmentation in biologically compromised non-unions, but it should not be viewed as a substitute for sound orthopedic surgical principles.

When MSC therapy is most likely to help. Atrophic non-unions (the "biological failure" type where the fracture gap is empty and acellular), early-stage osteonecrosis before femoral head collapse, and augmentation of bone grafting procedures in patients with poor endogenous healing capacity — smokers, diabetics, elderly patients — represent the scenarios with the strongest evidence of benefit.

When it is least likely to help. Hypertrophic non-unions (where the biology is intact but fixation is inadequate), infected non-unions without concurrent infection control, and established femoral head collapse with degenerative joint changes — these require mechanical or surgical solutions, not cellular augmentation alone.

Timeline expectations. Radiographic evidence of callus progression can appear as early as 6–8 weeks post-treatment, but clinical union typically requires 12–24 weeks depending on fracture location, size, and patient factors. This is not an instant fix — it is a biological process that MSCs accelerate and support, but do not circumvent.

Combining MSC Therapy with Optimized Surgical Principles

MSC therapy is not a standalone treatment for non-union; it works best as part of a comprehensive surgical strategy. Stable fixation — whether via intramedullary nailing, plate osteosynthesis, or external fixation — remains the mechanical prerequisite for any biological graft to function. MSCs cannot bridge a fracture gap that moves with every step. The combination of revision fixation (if needed), MSC delivery to the non-union site, and optimization of the patient's metabolic and nutritional status (normalizing Vitamin D levels above 30 ng/mL, ensuring adequate protein and calcium intake, smoking cessation) represents the current best-practice framework for biological augmentation of fracture healing [18].

Frequently Asked Questions

How does MSC therapy compare to autologous bone grafting for non-union?

Current RCT-level evidence suggests MSC therapy achieves comparable union rates to iliac crest bone grafting (approximately 80–85% at 12 months) while avoiding donor-site morbidity — the chronic hip pain that affects roughly one-third of bone graft harvest patients. This makes MSC therapy particularly attractive for patients who are poor surgical candidates or who wish to avoid a second surgical site [16].

Which type of MSCs work best for bone healing?

Bone marrow-derived MSCs have the deepest preclinical track record and most natural osteogenic potential. However, Wharton's jelly-derived MSCs offer practical advantages — higher proliferation rates, greater consistency between donors, and non-invasive collection — while demonstrating comparable osteogenic differentiation capacity in vitro. The choice often depends on availability and regulatory context rather than clear efficacy differences, as no head-to-head human trial has directly compared MSC sources for fracture healing.

How are the MSCs delivered to the fracture site?

MSCs can be delivered via direct percutaneous injection (minimally invasive, image-guided, for well-aligned non-unions), combined with a scaffold carrier (calcium phosphate, demineralized bone matrix, or synthetic polymers that provide osteoconductive structure), or seeded onto a structural graft for large segmental defects. The choice depends on defect size, mechanical requirements, and surgeon preference. Scaffold-based delivery tends to show higher cell retention and more consistent bone formation in critical-size defects compared to suspension injection alone [12].

What is the recovery timeline after MSC treatment for a non-union fracture?

Most protocols involve a period of protected weight-bearing for 6–12 weeks post-treatment, with serial X-rays to monitor callus progression. Clinical union — defined as pain-free weight-bearing with radiographic bridging across at least three of four cortices — typically occurs between 12 and 24 weeks. Full remodeling and return to unrestricted activity may take 6–12 months. Physical therapy begins once radiographic union is confirmed, with progressive loading to stimulate remodeling along stress lines.

Is MSC therapy for bone healing safe?

The safety profile of MSC therapy for orthopedic applications is well-established across thousands of patients. The most comprehensive meta-analysis available, encompassing over 3,000 patients who received MSCs for musculoskeletal conditions, reported no cases of tumor formation, no significant systemic adverse events, and a local complication rate (infection, hematoma) comparable to standard orthopedic procedures. The ISCT consensus position is that culture-expanded MSCs carry minimal risk when manufactured under GMP conditions and administered in accordance with established protocols [19].

How much does MSC therapy for bone fractures cost in Thailand?

At VELAR Center in Bangkok, MSC therapy for orthopedic applications is priced substantially below equivalent treatment in North America or Europe, where single-procedure costs routinely exceed $15,000–25,000. Treatment costs vary depending on the cell dose required, whether a scaffold or carrier is used, and whether concurrent surgical fixation is needed. A detailed, personalized quote is provided after imaging review and clinical assessment during the initial consultation.

Limitations and What the Evidence Does Not Support

This is an honest assessment of where the evidence stands. MSC therapy for bone healing is not FDA-approved for this indication in the United States and remains investigational in most jurisdictions. The clinical evidence, while consistently positive, comes predominantly from small single-center studies and a handful of modestly sized RCTs — the field lacks the large, multicenter, sham-controlled phase III trials that would definitively establish efficacy. Heterogeneity in MSC source, dose, carrier, and delivery method makes cross-study comparison difficult. The ideal cell dose, optimal timing, and best delivery vehicle remain areas of active investigation rather than settled science. Patients considering MSC therapy for fracture healing should understand these limitations and make decisions in consultation with both their orthopedic surgeon and a regenerative medicine specialist [20].

References

  1. Zura R, Xiong Z, Einhorn T, et al. Epidemiology of fracture nonunion in 18 human bones. JAMA Surgery. 2016;151(11):e162775. doi:10.1001/jamasurg.2016.2775 ↩
  2. Gómez-Barrena E, Rosset P, Lozano D, et al. Bone fracture healing: cell therapy in delayed unions and nonunions. Bone. 2015;70:93-101. doi:10.1016/j.bone.2014.07.033 ↩
  3. Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. Nature Reviews Rheumatology. 2015;11(1):45-54. doi:10.1038/nrrheum.2014.164 ↩
  4. Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. The Scientific World Journal. 2012;2012:606404. doi:10.1100/2012/606404 ↩
  5. Bahney CS, Zondervan RL, Allison P, et al. Cellular biology of fracture healing. Journal of Orthopaedic Research. 2019;37(1):35-50. doi:10.1002/jor.24170 ↩
  6. Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nature Reviews Rheumatology. 2012;8(3):133-143. doi:10.1038/nrrheum.2012.1 ↩
  7. Calori GM, Albisetti W, Agus A, et al. Risk factors contributing to fracture non-unions. Injury. 2007;38 Suppl 2:S11-S18. doi:10.1016/S0020-1383(07)80004-0 ↩
  8. Oryan A, Kamali A, Moshiri A, Baghaban Eslaminejad M. Role of mesenchymal stem cells in bone regenerative medicine: what is the evidence? Cells Tissues Organs. 2017;204(2):59-83. doi:10.1159/000469704 ↩
  9. Grayson WL, Bunnell BA, Martin E, et al. Stromal cells and stem cells in clinical bone regeneration. Nature Reviews Endocrinology. 2015;11(3):140-150. doi:10.1038/nrendo.2014.234 ↩
  10. Qin Y, Wang L, Gao Z, et al. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. Scientific Reports. 2016;6:21961. doi:10.1038/srep21961 ↩
  11. Schlundt C, El Khassawna T, Serra A, et al. Macrophages in bone fracture healing: their essential role in endochondral ossification. Bone. 2018;106:78-89. doi:10.1016/j.bone.2015.10.019 ↩
  12. Giannotti S, Trombi L, Bottai V, et al. Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessment. PLoS One. 2013;8(8):e73893. doi:10.1371/journal.pone.0073893 ↩
  13. Berner A, Reichert JC, Woodruff MA, et al. Autologous vs. allogenic mesenchymal progenitor cells for the reconstruction of critical-sized segmental tibial bone defects in aged sheep. Acta Biomaterialia. 2013;9(8):7874-7884. doi:10.1016/j.actbio.2013.04.035 ↩
  14. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions: influence of the number and concentration of progenitor cells. Journal of Bone and Joint Surgery American Volume. 2005;87(7):1430-1437. doi:10.2106/JBJS.D.02215 ↩
  15. Hernigou P, Guissou I, Homma Y, et al. Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions decreases complications in patients with diabetes. International Orthopaedics. 2015;39(8):1639-1643. doi:10.1007/s00264-015-2732-4 ↩
  16. Gómez-Barrena E, Rosset P, Gebhard F, et al. Feasibility of allogeneic mesenchymal stromal cells in nonunion treatment: the ORTHOUNION pilot. Bone. 2021;144:115798. doi:10.1016/j.bone.2020.115798 ↩
  17. Piuzzi NS, Chahla J, Schrock JB, et al. Evidence for the use of cell-based therapy for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. Journal of Arthroplasty. 2017;32(5):1698-1708. doi:10.1016/j.arth.2016.12.049 ↩
  18. Nauth A, Schemitsch E, Norris B, et al. Critical-size bone defects: is there a consensus for diagnosis and treatment? Journal of Orthopaedic Trauma. 2018;32 Suppl 1:S7-S11. doi:10.1097/BOT.0000000000001115 ↩
  19. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  20. Ho-Shui-Ling A, Bolander J, Rustom LE, et al. Bone regeneration strategies: engineered scaffolds, bioactive molecules and stem cells — current stage and future perspectives. Biomaterials. 2018;180:143-162. doi:10.1016/j.biomaterials.2018.07.017 ↩